STOCK TITAN

[Form 4] Guardant Health, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Guardant Health (GH) filed a Form 4 disclosing an insider sale. Director Myrtle S. Potter sold 26 shares of common stock on 10/17/2025 at $66.95 per share. After this transaction, she directly beneficially owns 18,324 shares. The filing lists the ownership form as direct and does not report any derivative security activity.

Guardant Health (GH) ha presentato un Modulo 4 che rivela una vendita da insider. la direttrice Myrtle S. Potter ha venduto 26 azioni ordinarie il 17/10/2025 a 66,95 USD per azione. Dopo questa operazione, possiede direttamente 18.324 azioni. Il modulo indica la forma di possesso come diretta e non riporta alcuna attività di strumenti derivati.

Guardant Health (GH) presentó un Formulario 4 divulgando una venta de insiders. La directora Myrtle S. Potter vendió 26 acciones ordinarias el 17/10/2025 a 66,95 USD por acción. Después de esta operación, posee directamente 18.324 acciones. La presentación indica la forma de propiedad como directa y no reporta ninguna actividad de valores derivados.

Guardant Health (GH)가 내부자 매출을 공개하는 Form 4를 제출했습니다. 이사 Myrtle S. Potter는 2025년 10월 17일 주당 66.95달러로 보통주 26주를 매도했습니다. 이 거래 후 그녀는 직접적으로 18,324주를 보유하게 됩니다. 제출 문서는 소유 형태를 직접 형태로 보고하며 파생증권 활동은 보고하지 않습니다.

Guardant Health (GH) a déposé le formulaire 4 divulguant une vente d'initié. La directrice Myrtle S. Potter a vendu 26 actions ordinaires le 17/10/2025 à 66,95 USD par action. Après cette opération, elle détient directement 18 324 actions. Le dépôt indique que la forme de propriété est directe et ne signale aucune activité de valeur mobilière dérivée.

Guardant Health (GH) hat ein Form 4 eingereicht, das einen Insiderverkauf offenlegt. Direktorin Myrtle S. Potter verkaufte am 17.10.2025 26 Stammaktien zu 66,95 USD je Aktie. Nach dieser Transaktion besitzt sie direkt und vorteilhaft 18.324 Aktien. Die Einreichung listet die Eigentumsform als direkt auf und meldet keine Aktivität mit Derivaten.

قدمت Guardant Health (GH) نموذج 4 يكشف عن بيع من الداخل. كتبت المديرة ميتلير س. بوتر بيع 26 سهماً من الأسهم العادية في 17/10/2025 بسعر 66.95 دولار للسهم الواحد. بعد هذه الصفقة، تمتلك مباشرة وبشكل مفيد 18,324 سهماً. تشير الوثيقة إلى شكل الملكية كـ مباشر ولا تذكر أي نشاط للأوراق المالية المشتقة.

Guardant Health (GH) 提交了 Form 4,披露内部人出售。 董事 Myrtle S. Potter 于 2025/10/17 以每股 66.95 美元出售 26 股普通股。交易后,她直接受益持有 18,324 股。 文件将所有权形式列为直接,并未报告任何衍生证券活动。

Positive
  • None.
Negative
  • None.

Guardant Health (GH) ha presentato un Modulo 4 che rivela una vendita da insider. la direttrice Myrtle S. Potter ha venduto 26 azioni ordinarie il 17/10/2025 a 66,95 USD per azione. Dopo questa operazione, possiede direttamente 18.324 azioni. Il modulo indica la forma di possesso come diretta e non riporta alcuna attività di strumenti derivati.

Guardant Health (GH) presentó un Formulario 4 divulgando una venta de insiders. La directora Myrtle S. Potter vendió 26 acciones ordinarias el 17/10/2025 a 66,95 USD por acción. Después de esta operación, posee directamente 18.324 acciones. La presentación indica la forma de propiedad como directa y no reporta ninguna actividad de valores derivados.

Guardant Health (GH)가 내부자 매출을 공개하는 Form 4를 제출했습니다. 이사 Myrtle S. Potter는 2025년 10월 17일 주당 66.95달러로 보통주 26주를 매도했습니다. 이 거래 후 그녀는 직접적으로 18,324주를 보유하게 됩니다. 제출 문서는 소유 형태를 직접 형태로 보고하며 파생증권 활동은 보고하지 않습니다.

Guardant Health (GH) a déposé le formulaire 4 divulguant une vente d'initié. La directrice Myrtle S. Potter a vendu 26 actions ordinaires le 17/10/2025 à 66,95 USD par action. Après cette opération, elle détient directement 18 324 actions. Le dépôt indique que la forme de propriété est directe et ne signale aucune activité de valeur mobilière dérivée.

Guardant Health (GH) hat ein Form 4 eingereicht, das einen Insiderverkauf offenlegt. Direktorin Myrtle S. Potter verkaufte am 17.10.2025 26 Stammaktien zu 66,95 USD je Aktie. Nach dieser Transaktion besitzt sie direkt und vorteilhaft 18.324 Aktien. Die Einreichung listet die Eigentumsform als direkt auf und meldet keine Aktivität mit Derivaten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
POTTER MYRTLE S

(Last) (First) (Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CA 94304

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/17/2025 S 26 D $66.95 18,324 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ John G. Saia, as attorney-in-fact for Myrtle S. Potter 10/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did GH report on Form 4?

Myrtle S. Potter, a director, sold 26 shares of common stock at $66.95 on 10/17/2025.

How many Guardant Health shares does the reporting person hold after the sale?

Following the transaction, the reporting person directly beneficially owns 18,324 shares.

What is the relationship of the reporting person to Guardant Health (GH)?

The reporting person is a Director of Guardant Health, Inc.

What was the ownership form disclosed for the remaining GH shares?

The filing shows Direct (D) ownership for the remaining shares.

Were any derivative securities reported in this Form 4?

No. The form does not list any derivative securities transactions.

Who signed the Form 4 for this transaction?

It was signed by /s/ John G. Saia, as attorney-in-fact for Myrtle S. Potter, dated 10/20/2025.
Guardant Health

NASDAQ:GH

GH Rankings

GH Latest News

GH Latest SEC Filings

GH Stock Data

8.16B
119.27M
4.5%
99.11%
6.43%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO